<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did Exicure's operating expenses trend in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/8/2025 12:37am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Exicure's operating expenses in Q4 2024 were not available. However, the company's General and Administrative (G&amp;A) expenses were significantly reduced compared to the previous year. The G&amp;A expense for the year ended December 31, 2024, was $5.4 million, down from $11.7 million in the year ended December 31, 2023. This decrease was due to higher costs in 2023 related to separation pay of former executives and related stock-based compensation expense, payroll and related benefits, legal and consulting fees, facility and lease costs, and depreciation from property and equipment. Additionally, the Research and Development (R&amp;D) expense for the year ended December 31, 2024, was $0, reflecting the stoppage of clinical, preclinical, and discovery program activities and a reduction in employee headcount.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:D,comeFrom:"AInvestShareLink",events:[],answerSource:h}],fetch:{},error:i,state:{sharePreviewModule:{loadJgySuccess:g,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:h,cache_builder:a,reply_action:"Answer",execute_mode:t,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did Exicure's operating expenses trend in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did Exicure's operating expenses trend in Q4 2024?\",\"user_id\":\"dp89125190\",\"user_name\":\"\",\"trace_id\":\"9b42ed31-8f64-4564-ae14-d26949ff031b\",\"session_id\":\"9b42ed31-8f64-4564-ae14-d26949ff031b\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:u,title:E,summary:F,full_summary:"CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. We continue to engage in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization. 2024 Financial Results Cash Position: Cash and cash equivalents were $12.5 million as of December 31, 2024, as compared to $0.8 million as of December 31, 2023. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be needed to fund our ongoing operations and exploration of strategic alternatives and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $0 for the year ended December 31, 2024, as compared to $1.4 million for the year ended December 31, 2023. The decrease in R&D expense for the year ended December 31, 2024 of $1.4 million reflects the stoppage of clinical, preclinical, and discovery program activities and a reduction in employee headcount in December 2021 and September 2022. The Company began exploring strategic alternatives in April 2023. As a result, the Company determined it was no longer appropriate to record any research and development expenses after the first quarter of 2023. General and Administrative (G&A) Expense: General and administrative expenses were $5.4 million for the year ended December 31, 2024, as compared to $11.7 million for the year ended December 31, 2023. The decrease in G&A expense of $6.3 million for the year ended Decembe",url:G,image_url:a,video_url:a,publish_time:H,search_extra_info:{search_burial_info:{id:v,uid:I,ab:{scene_id:J,layer_exp:[{layer_id:K,exp_id:L}]}}},simhash:"10f94fc50f8b71aa",msg_id:v}}],answer_chain_name:M,agent_mode:N,native_answer:a,come_from:a,text_answer:D,trace_id:e,cost:14376,event_names:a,question:d,fallback_type:O,input_type:P,fall_back_reason:{fall_back_type:O,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:e,first_return_cost:2223,cache_type:"no_cache",question_id:e,transfer_question:d,signal_type:"ON_COMPLETE",start_time:w,remote_svc:h,slots:[],answer_type:t,user_id:p,skill_name:x},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:e,session_id:e,user_id:p,question:d,source:h,raw_question:d,version:"3.4.1",action_name:x,nlu:{entity:[{type:Q,value:"XCUR.O",market:R}]},output_time:w,deep_research:c,deep_thinking:c,agent_mode:N},extra:{}},{answer_path:j,section:{id:k,info_texts:["Thinking"],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:j,section:{id:k,info_texts:["Querying Stock: XCUR Operating Expenses in Q4 2024"],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b,status:S},logs:[],extra:{action:"Querying Stock",action_input:"XCUR Operating Expenses in Q4 2024",thought:"The user seeks to analyze Exicure's operating expenses in Q4 2024. I should focus on its Q4 2024 operating expenses data. I will use FinQuery for the data mentioned above."}},{answer_path:f,section:{id:y,info_texts:[],show_type:q,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:k,info_texts:["Searching Web: Exicure operating expenses in Q4 2024"],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b,status:S},logs:[],extra:{action:"Searching Web",action_input:"Exicure operating expenses in Q4 2024",thought:"I am unable to obtain Exicure's Q4 2024 operating expenses by FinQuery, now I will try again using Search."}},{answer_path:f,section:{id:y,info_texts:[],show_type:q,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:y,info_texts:[],show_type:q,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:k,info_texts:["Generating Answer"],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:f,section:{id:z,info_texts:[],show_type:A,voice_txt:"Ex",text_answer:T,rich_text:T,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:2000,info_texts:[],show_type:A,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:G,image_url:a,video_url:a,title:E,summary:F,index:u,publish_time:H,search_id:v,search_uid:I,search_ab:{scene_id:J,layer_exp:[{layer_id:K,exp_id:L}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:z,info_texts:[],show_type:A,voice_txt:". This",text_answer:U,rich_text:U,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:f,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"XCUR",market_id:R,name:V,domain:Q},pos:g,section_id:z,txt:V,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:k,info_texts:["Completed"],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:m,query_text:m,trace_info:{item_id:"1ca021d7f0ca8ad6b63a908ded5c7a27",item_type:r,item_name:m,rec_info:W}},{display_text:n,query_text:n,trace_info:{item_id:"f6d23a44622937c6674dc89bb8d02c6f",item_type:r,item_name:n,rec_info:X}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:g,type:"1",display2:c,url:a}},request_config:[{source_type:3,related_name:Y}],puuid:B,tag:a,category:"custom",uuid:Z}],global:{urp_static_data:[{name:Y,value:{status_code:g,columns:[{type:o,index_name:_,key:_},{type:o,index_name:$,key:$},{type:o,index_name:aa,key:aa},{type:o,index_name:ab,key:ab},{type:o,index_name:ac,key:ac}],datas:[{send_text:m,item_type:r,rec_info:W,display_text:m,rec_reason:a},{send_text:n,item_type:r,rec_info:X,display_text:n,rec_reason:a}],dataSize:u,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ad,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:s,"min-height":"100%",position:ae,height:s},isMaterial:c,id:ad,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:g,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:C,componentUuid:Z,script:[{name:af,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:C,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:C},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:s,position:ae,height:s},isMaterial:b,_id:19,id:af,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:ag,voice_txt:a,tracking_info:{},uuid:B},order:{is_auto:c,render_for:ag,chart_type:"command",puuid:B}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:q,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:x,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:t,answer_chain_name:M},is_deep_research:c,deep_thinking:c,create_time:1746679078861},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:i,docsData:[],quoteData:i},tplType:"question"},events:ah,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:ah,client_ip:a,question:d,user_id:p,user_name:a,trace_id:e,session_id:e,source:h,input_type:P}}],userId:p,userName:a,startTime:w,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:i,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:g,traceTableData:i,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-exicures-operating-expenses-trend-in-q4-2024-42665f\u002F",config:{_app:{basePath:ai,assetsPath:ai,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"How did Exicure's operating expenses trend in Q4 2024?","9b42ed31-8f64-4564-ae14-d26949ff031b","other\u002FopenAnswer",0,"ths_ainvest_lite_web",null,"progress\u002Fsearching_for",1000,"searching_for","🤖 What was Exicure's total operating expense in Q4 2024?","💻 What percentage of Exicure's revenue were operating expenses in Q4 2024?","STR","dp89125190","signal","llm_generated","auto","agent",2,"38d59e21bd4c8a67_1",1746679064485,"inspect stocks",999,2001,"rich_text","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Exicure's operating expenses in Q4 2024 were not available. However, the company's General and Administrative (G&A) expenses were significantly reduced compared to the previous year. The G&A expense for the year ended December 31, 2024, was $5.4 million, down from $11.7 million in the year ended December 31, 2023. This decrease was due to higher costs in 2023 related to separation pay of former executives and related stock-based compensation expense, payroll and related benefits, legal and consulting fees, facility and lease costs, and depreciation from property and equipment. Additionally, the Research and Development (R&D) expense for the year ended December 31, 2024, was $0, reflecting the stoppage of clinical, preclinical, and discovery program activities and a reduction in employee headcount.","Exicure, Inc. Reports Full Year 2024 Financial Results","The decrease in G&A expense of $6.3 million for the year ended December 31, 2024 was due to higher costs in 2023 from separation pay of former executives and related stock based compensation expense, payroll and related benefits, legal and consulting fees, facility and lease costs, depreciation from...","https:\u002F\u002Fwww.businesswire.com\u002Fnews\u002Fhome\u002F20250318788523\u002Fen\u002FExicure-Inc.-Reports-Full-Year-2024-Financial-Results","2024-12-30","38d59e21bd4c8a67","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","186","thinking","Exicure's operating expenses in Q4 2024 were not available. However, the company's General and Administrative (G&A) expenses were significantly reduced compared to the previous year. The G&A expense for the year ended December 31, 2024, was $5.4 million, down from $11.7 million in the year ended December 31, 2023[^2]",". This decrease was due to higher costs in 2023 related to separation pay of former executives and related stock-based compensation expense, payroll and related benefits, legal and consulting fees, facility and lease costs, and depreciation from property and equipment[^2]. Additionally, the Research and Development (R&D) expense for the year ended December 31, 2024, was $0, reflecting the stoppage of clinical, preclinical, and discovery program activities and a reduction in employee headcount[^2].","Exicure","2+679_496_21_554+0+0+9b42ed31-8f64-4564-ae14-d26949ff031b+1ca021d7f0ca8ad6b63a908ded5c7a27+llm_generated+aimeTagAnalysis+0+0.045485686510801315+1","2+679_496_21_554+0+0+9b42ed31-8f64-4564-ae14-d26949ff031b+f6d23a44622937c6674dc89bb8d02c6f+llm_generated+aimeTagAnalysis+0+0.01361166499555111+2","recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>